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trial. The National Cancer Institute has launched the
national lung screening trial, a controlled study of
50 000 people that randomises participants to chest
screening by computed tomography or x ray and uses
mortality as an end point. It is the right way to address
this issue, but it could take a decade to produce an
answer.
How should patients, especially those who smoke,
be advised in the meantime? After providing
counselling for nicotine dependence doctors could
suggest that patients enrol in the national lung screen-
ing trial or similar trials. If patients simply want to get
scanned, doctors should take the time to discuss the
pros and cons. Doctors without financial conflicts of
interest are best positioned to give balanced informed
consent. As patients’ fiduciary, doctors should tell
patients in explicit terms that such screening has no
proved benefit and that serious risks could outweigh
benefits (if there are any). Patients should understand
that the stakes are high.
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Failures of the therapeutic chain as a cause of drug
ineffectiveness
Promotion, misinformation, and economics work better than needs
Failure of drug treatment may be due to wrongdiagnosis, selection of an inappropriate drug ordosage, use of an adulterated or fake drug, the
patient’s non-adherence, a drug’s poor bioavailability
or lack of efficacy, medication error, or occurrence of
an adverse reaction. The potential causes of therapeu-
tic failure depend on a complex interplay of social and
medical factors. Failures can occur at every step of the
therapeutic chain, which is the process describing the
life of medicines in a community. This process includes
development, regulation (including registration), mar-
keting, distribution, prescription, dispensing, and use
of the drug.1
The following are only some examples of failures
in drug treatment. In 2001 the top five best selling
medicines globally were atorvastatin, omeprazole, sim-
vastatin, lansoprazole, and amlodipine, although avail-
able evidence indicates that only two of these drugs are
first choice in their class. In recent years, various
non-essential non-innovative drugs had to be with-
drawn from the market because of serious adverse
effects after a few years of growth in sales. One of these
drugs, troglitazone, was associated with a risk of liver
failure, which had been played down by the
manufacturing company.2 More recently, serious flaws
in the published pivotal trial that served as the basis for
the global promotion of celecoxib were made public,3
and alosetron was reapproved by FDA amid accusa-
tions that the FDA had become a servant of the drug
industry.4
Prescription patterns are far from optimal.
Although evidence supports thiazide diuretics as the
treatment of first choice of hypertension, angiotensin
converting enzyme inhibitors and calcium channel
blockers are the most consumed antihypertensive
drugs. Although in multiple sclerosis azathioprine is
backed by better evidence of long term efficacy and
(perhaps because) it is 125 times cheaper than
interferon beta, interferon beta is the preferred
treatment in many specialised centres.5 In the United
States adverse drug effects rank fourth to sixth in the
list of causes of death.6 Ineffective drugs, such as
cinnarizine or bovine gangliosides, have been identi-
fied in clinical trials and voluntary reporting systems as
causes of serious adverse effects.7 8
How are these and many other failures possible?
Firstly, the methods and objectives of medical research
are driven mainly by industrial priorities and the
fulfilment of regulatory requirements, rather than by a
conceptual framework that aims to answer questions
that arise in medical practice. Clinical trials are
designed to evaluate drugs rather than patients or
diseases.
Secondly, the term efficacy is merely a higher prob-
ability of clinical improvement, compared with
placebo, in selected end points that may have varying
clinical relevance. The implication is that in practice
therapeutic failure is, and should be, common. In addi-
tion, efficacy does not necessarily translate into
effectiveness in usual practice.9
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Thirdly, drug regulatory agencies grant market
authorisations for new drugs on the basis of a set of
standards, which have been suggested by the
International Conference on Harmonisation of Tech-
nical Requirements for Registration of Pharmaceuti-
cals for Human Use, whose secretariat is provided by
the International Federation of Pharmaceutical Manu-
facturers Associations. The international conference
has established detailed standards for drug develop-
ment, but it has not shown much interest in developing
standards for the review of obsolete drugs, the
provision of information to prescribers and consum-
ers, the use of international non-proprietary names of
medicines, transparency about pricing, international
norms to control promotion and advertising, transpar-
ency in drug safety monitoring, or access to
information.
Market authorisations tend to be granted on the
basis of superiority over placebo or non-inferiority
with respect to alternative treatments rather than on
the basis of relative efficacy and cost benefit.10 While
the ratio of therapeutic benefit to risk of drugs depends
on the circumstances surrounding their use, agencies
regulating drugs increasingly tend to assess quality,
efficacy, and safety as if these were independent of the
way and the context in which drugs are prescribed, dis-
pensed, and used. The result is that drug and industry
oriented clinical research and regulation are leading to
drug and industry driven therapeutic practice.
Fourthly, pharmaceutical companies have an
increasing direct or indirect influence on the
mechanisms of drug selection and purchasing in
healthcare systems. In the United States, most health
maintenance organisations subcontract with pharma-
ceutical benefits managers who negotiate prices of
prescriptions with pharmacies, institute mandatory
generic substitution programmes, and develop pur-
chase agreements with manufacturers. Several of the
largest pharmaceutical benefits management organisa-
tions have been purchased by pharmaceutical compa-
nies, which in 1994 controlled 113 million people
enrolled with health maintenance organisations..11 In
the European Union drugs are generally reimbursed
according to their market value rather than their thera-
peutic value, and the result is that new drugs, which are
more expensive than old established ones (and
therefore generate more profits), are most heavily pro-
moted.
Fifthly, the marketing budgets of the pharmaceuti-
cal industry are larger than the research and develop-
ment costs. The industry increasingly controls scientific
societies and continuing medical education, and this
has become a new marketing strategy. It is a failure that
healthcare systems, where decisions are based on
knowledge, do not consider continuing education as a
strategic priority and that the field has been left prima-
rily to the technology industry.
Sixthly, the trade related intellectual property rights
agreement of the World Trade Organization, which
grants patents for 20 years, has an important negative
effect on the equitable access of populations to drugs.
In addition, it makes companies concentrate their pro-
motional efforts on the newest and most expensive
drugs while they are protected by a patent. Lack of
access to essential drugs is certainly a failure.
Finally, the opportunity for therapeutic failure is
especially high in less developed countries, where the
standards of regulation, quality control, training of
health professionals, financial access, and drug and
therapeutic information are low if they exist at all.
Much can be done at all stages of the therapeutic
chain. Medicine is deeply and increasingly embedded
with market values and industrial culture. Research
skills have to be built up inside the health system, which
is the natural laboratory of clinical pharmacology. The
new information technologies may be of great help to
set up networks of health professionals, which should
monitor what is relevant, feasible, necessary, and effec-
tive in therapeutics.12 Large changes of prescription
patterns cannot be achieved by passive transfer of
information, and so a need exists to build up a critical
mass of professionals practising in the healthcare
system and involved in research that should produce
knowledge rather than mere information.
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